OPKO Health Executive Vice President Steven Rubin Sells 53,266 Shares at $1.22 Per Share

Details of the Share Disposition at OPKO Health

Steven D. Rubin, who holds the position of Executive Vice President of Administration in addition to serving as a Director at OPKO Health, Inc., completed a share transaction on July 24, 2026. The disposition involved 53,266 shares of the company's common stock, with a par value of $0.01 per share. The filing indicates that these shares were disposed of at a price of $1.22 per share, representing a standard equity market transaction.

The nature of this transaction differs from a voluntary market sale. According to the regulatory disclosure, the 53,266 shares represent common stock that was withheld to satisfy tax withholding obligations arising from the vesting of restricted stock units held by Rubin. This type of transaction is a routine occurrence for executives whose compensation includes equity awards subject to vesting schedules and associated tax liabilities. The withholding mechanism allows executives to meet their tax obligations through the automatic retention of a portion of vested shares rather than requiring a separate cash payment.

Rubin's Ongoing Beneficial Ownership Position

Following the July 24, 2026 transaction, Rubin maintained direct beneficial ownership of 6,571,966 shares of OPKO Health common stock. This substantial shareholding underscores Rubin's significant financial interest in the company's performance and strategic direction. The size of his ownership stake suggests ongoing confidence in the organization's long-term prospects, despite the tax-driven share disposition during the reporting period.

Beneficial ownership calculations under Section 16 of the Securities Exchange Act of 1934 include shares held directly by the reporting person, as well as shares over which the person may exercise voting or investment control. In this case, Rubin's 6,571,966 shares are held in direct form, meaning he has immediate ownership and control over these securities without indirect arrangements or holding structures. The regulatory filing provides transparency to investors regarding the equity stakes held by senior company insiders.

Executive Compensation Structure and Restricted Stock Units

The transaction documented in the July 28, 2026 filing reflects a standard component of executive compensation arrangements at publicly traded healthcare companies like OPKO Health. Restricted stock units, or RSUs, are common equity-based compensation tools that vest according to predetermined schedules, typically tied to continued employment or the achievement of performance milestones. When RSUs vest, they are converted into shares of common stock, and the executive becomes liable for income and employment taxes on the value of the vested shares.

Rather than requiring executives to liquidate other holdings or make separate cash payments to cover these tax liabilities, many companies implement withholding programs. Under these programs, the employer automatically retains a number of shares equal to the estimated tax obligation and transfers them to government tax authorities on behalf of the executive. This mechanism simplifies tax administration and ensures timely payment of withholding taxes. The 53,266 shares disposed of by Rubin on July 24, 2026 represent shares withheld under this standard practice, not a discretionary sale decision made by the executive.

Rubin's Roles and Responsibilities at OPKO Health

Steven D. Rubin serves OPKO Health in dual capacities, functioning as both an Executive Vice President of Administration and as a member of the company's Board of Directors. These positions reflect significant responsibility within the organization's management and governance structures. As Executive Vice President of Administration, Rubin likely oversees critical operational functions including human resources, facilities, compliance, and administrative services. His Board membership provides him with insight into strategic decisions and places him among the senior decision-making body responsible for shareholder oversight.

The combination of executive and board-level roles demonstrates that Rubin holds a position of considerable influence and trust within OPKO Health. Individuals in such positions are subject to heightened regulatory scrutiny regarding their securities transactions, as mandated by Section 16 of the Securities Exchange Act. The public disclosure of his equity transactions, holdings, and any changes thereto serves to protect investor interests by providing transparency regarding trading activity by company insiders who possess access to material non-public information.

Regulatory Filing and Disclosure Requirements

The disclosure of Rubin's share transaction was made through a Form 4 filing, the standard regulatory document that officers, directors, and significant shareholders must submit to the SEC to report changes in beneficial ownership of company securities. The filing was submitted on July 28, 2026, four calendar days after the July 24, 2026 transaction date. These filings are required under Section 16(a) of the Securities Exchange Act and must be submitted within two business days following the transaction, with limited exceptions.

Form 4 disclosures serve as a critical mechanism for maintaining market transparency and preventing insider trading abuse. By requiring prompt public reporting of insider transactions, the regulatory framework allows other investors to monitor the trading activity of company insiders and potentially incorporate such information into their own investment decisions. The detailed information required on Form 4 filings includes transaction dates, prices, quantities, and the resulting beneficial ownership positions, providing a comprehensive record of insider equity activity.

Tax Implications and Equity Award Management

The withholding of shares to satisfy tax obligations represents one of several tax-efficient approaches employed by companies to manage the tax consequences of equity compensation awards. When restricted stock units vest, the recipient is treated as having received ordinary income equal to the fair market value of the shares on the vesting date. For executives in high tax brackets, this income recognition can result in substantial tax liabilities. The withholding mechanism documented in the July 24, 2026 transaction allowed Rubin's employer to satisfy these withholding obligations through share retention rather than requiring alternative funding sources.

The transaction price of $1.22 per share recorded in the filing reflects the fair market value of OPKO Health common stock on the transaction date. This valuation is critical for accurate tax reporting and forms the basis for calculating the executive's tax liability and the number of shares required to be withheld. By implementing systematic withholding programs, publicly traded companies like OPKO Health can streamline the tax administration process while ensuring compliance with federal and state withholding requirements.

Investor Implications and Insider Trading Oversight

The disclosure of insider transactions by executives like Rubin provides investors with valuable information regarding the confidence levels and strategic positioning of company leadership. While tax-driven share dispositions such as withholdings for RSU vesting are routine administrative transactions, the overall pattern of insider buying and selling activity can offer insights into management's views on company valuation and prospects. Investors monitoring insider trading activity may track whether company insiders are increasing or decreasing their equity stakes through discretionary transactions separate from tax-obligation withholdings.

The regulatory framework governing insider trading and disclosure requirements is designed to prevent information asymmetries between company insiders and public investors. By requiring prompt disclosure of all transactions in company securities by officers, directors, and substantial shareholders, the SEC seeks to maintain fair and orderly markets. Rubin's continued substantial ownership of 6,571,966 shares demonstrates his alignment with shareholder interests, despite the routine tax-driven share disposition documented in the July 2026 filing.

OPKO Health's Equity Compensation Program

The transaction disclosed in Rubin's Form 4 filing reflects OPKO Health's utilization of equity-based compensation as a component of executive remuneration. Restricted stock units represent a form of deferred equity compensation that has become increasingly common in the healthcare and life sciences sectors. These awards align executive incentives with shareholder value creation by tying compensation to stock performance and continued employment. The vesting of RSUs held by senior executives like Rubin represents a natural progression of the company's compensation program and does not necessarily reflect any change in business conditions or strategic direction.

Many healthcare companies employ equity compensation programs to attract and retain executive talent in a competitive market. OPKO Health's use of RSUs for its executive leadership, as evidenced by Rubin's vesting transaction, indicates the company's reliance on equity-based incentive structures. The withholding of shares to satisfy associated tax obligations is a standard administrative practice that allows executives to focus on operational responsibilities while the company handles tax compliance procedures.

Market Context and Trading Activity

The July 24, 2026 transaction occurred at $1.22 per share, a price that investors may reference when evaluating OPKO Health's market valuation and trading patterns during the period. While the specific motivation for the July 2026 timing relates to RSU vesting schedules rather than market conditions, the transaction price provides a historical data point for investors tracking the company's stock performance. The regulatory disclosure makes this pricing information available to all market participants simultaneously, supporting fair and efficient market operations.

Investors seeking to monitor insider activity at OPKO Health can access comprehensive historical records of all Form 4 filings submitted by the company's officers, directors, and significant shareholders through the SEC's EDGAR database. This publicly available information allows individual and institutional investors to conduct ongoing analysis of insider trading patterns and make informed decisions regarding their own investment positions in the company.